Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Litoxetine - IXALTIS

Drug Profile

Litoxetine - IXALTIS

Alternative Names: IXA 001; SL 810385

Latest Information Update: 15 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi-Synthelabo
  • Developer IXALTIS
  • Class Antidepressants; Piperidines; Small molecules
  • Mechanism of Action Serotonin receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Urinary incontinence
  • Discontinued Major depressive disorder

Most Recent Events

  • 30 May 2019 IXALTIS completes a phase I/II clinical trial in Urinary incontinence in USA (PO) (NCT03397771)
  • 13 Mar 2019 Ixaltis completes a phase II trial in Urinary incontinence in France, Poland, United Kingdom (PO) (EudraCT2016-004307-30)
  • 10 Jan 2018 Phase-I/II clinical trials in Urinary incontinence in USA (PO) (NCT03397771)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top